ESR1 and breast cancer: Applying the drug-free prognostic signature to a total 521 samples of ER+ breast cancer patients receiving post-operative tamoxifen therapy, collected in the GSE17705, GSE12093 and GSE6532_tt1 datasets, we recognized a total 320 high-risk patients (184, 68 and 68 in the three datasets, respectively).